US Patent 9326991 Nucleotide prodrug compounds and use
Patent 9326991 was granted and assigned to Ligand Pharmaceuticals on May, 2016 by the United States Patent and Trademark Office.
All edits
Edits on 1 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 5 Dec, 2023
Golden AI
Edits made to:
Article (+251 characters)
Article
Patent abstract
Embodiments of the present invention include nucleoside 5′-monophosphate derivative compounds, their preparation and their uses. In some embodiments, nucleoside 5′-monophosphate derivative compounds are useful to treat viral infections.
Edits on 29 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
K. Raja Reddy0
Lin Zhi0
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09326991 Nucleotide prodrug compounds and use US Patent 9326991 Nucleotide prodrug compounds and use
Infobox
Patent Number
093269910
Patent Number
93269910
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
093269910
Date of Patent
May 3, 2016
0Patent Application Number
144281510
Date Filed
September 12, 2013
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Jan, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 09326991 Nucleotide prodrug compounds and use
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
09326991
Date of patent
May 3, 2016
Patent application number
14428151
Date Filed
September 12, 2013
Patent primary examiner
Find more entities like US Patent 9326991 Nucleotide prodrug compounds and use
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.